A Phase 2 interventional study of ONO-4538 and ONO-4538 in Advanced Non-small Cell Lung Cancer (NSCLC), sponsored by Ono Pharmaceutical Co. Ltd. Completed at 10 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 43rd largest by enrollment, is one of 5 that started in 2014, is one of 66 in phase 2, and was the 11th registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 63 that completed or were terminated, 44 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Ono Pharmaceutical Co. Ltd has 9 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.
Drug: ONO-4538
In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.
Drug: ONO-4538
Response Rate (Centrally Assessed)
Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\*100. 95% Confidence interval (CI) was calculated by Wilson method.
Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.
Response Rate (Investigator-assessed)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.
Overall Survival
Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.
Time frame: Follow-up phase: Every 6 months after the first day of treatment of the last subject enrolled in the study, until death or study completion.
Progression Free Survival (Centrally Assessed)
Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.
Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or until central PD was confirmed or data cut-off point.Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.
Duration of Response (Centrally Assessed)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.
Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase(up to approximately 10 months).Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.
| Milestone | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Started | 45 | 58 |
| Completed | 12 | 15 |
| Not completed | 33 | 43 |
| Withdrew: Did not receive the investigational product | 1 | 2 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Met an exclusion criteria | 0 | 1 |
| Withdrew: Adverse event | 3 | 10 |
| Withdrew: Disease progression | 20 | 27 |
| Withdrew: Other than above reasons | 3 | 0 |
Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\*100. 95% Confidence interval (CI) was calculated by Wilson method.
| percentage of participants | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Response Rate (Centrally Assessed) | 13.6 (6.4 to 26.7) | 19.6 (11.3 to 31.8) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| percentage of participants | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Response Rate (Investigator-assessed) | 18.2 (9.5 to 32.0) | 19.6 (11.3 to 31.8) |
Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.
| days | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Overall Survival | NA (249.0 to NA) | NA (291.0 to NA) |
Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.
| days | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Progression Free Survival (Centrally Assessed) | 67.0 (41.0 to 182.0) | 162.0 (43.0 to 216.0) |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.
| days | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Duration of Response (Centrally Assessed) | NA (145.0 to NA) | NA (85.0 to NA) |
Collected over From the start of the first dose of the investigational product to 28 days after the final dose or discontinuation, occurring 28 or fewer days after the final dose, or data cut-off point (June 2, 2015), whichever occurs first. Adverse events will be monitored and assessed before each dose and as needed based on clinical symptoms. Total assessment period: up to 10 months per participant.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Squamous Non-small Cell Lung Cancer (NSCLC) | 12/44 (27.3%) | 20/44 (45.5%) | 24/44 (54.5%) |
| Non-squamous Non-small Cell Lung Cancer (NSCLC) | 15/56 (26.8%) | 17/56 (30.4%) | 36/56 (64.3%) |
| Event | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| PneumoniaInfections and infestations | 5/44 | 4/56 |
| HypercalcaemiaMetabolism and nutrition disorders | 3/44 | 0/56 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/44 | 3/56 |
| PyrexiaGeneral disorders | 2/44 | 0/56 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/44 | 2/56 |
| Angina unstableCardiac disorders | 1/44 | 0/56 |
| DiarrhoeaGastrointestinal disorders | 1/44 | 0/56 |
| Inguinal herniaGastrointestinal disorders | 1/44 | 0/56 |
| Lung infectionInfections and infestations | 1/44 | 1/56 |
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/44 | 0/56 |
| Event | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 18/44 | 20/56 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/44 | 15/56 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/44 | 15/56 |
| PruritusSkin and subcutaneous tissue disorders | 6/44 | 12/56 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 9/44 | 9/56 |
| ConstipationGastrointestinal disorders | 8/44 | 11/56 |
| FatigueGeneral disorders | 7/44 | 11/56 |
| PyrexiaGeneral disorders | 7/44 | 8/56 |
| DiarrhoeaGastrointestinal disorders | 6/44 | 2/56 |
| NauseaGastrointestinal disorders | 6/44 | 6/56 |
| Age, Continuous(years) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| Median | 69.5 (40 to 80) | 63.5 (29 to 77) | 66.5 (29 to 80) |
| Age, Customized(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| <65 years | 14 | 30 | 44 |
| 65-<75 years | 21 | 20 | 41 |
| >=75 years | 9 | 6 | 15 |
| Sex: Female, Male(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| Female | 0 | 22 | 22 |
| Male | 44 | 34 | 78 |
| Region of Enrollment(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| South Korea | 44 | 56 | 100 |
| Histology(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| Squamous | 44 | 0 | 44 |
| Adenocarcinoma | 0 | 50 | 50 |
| Large cell carcinoma | 0 | 1 | 1 |
| Other | 0 | 5 | 5 |
| Disease stage(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| IIIB | 5 | 1 | 6 |
| IV | 37 | 54 | 91 |
| Recurrent | 2 | 1 | 3 |
| Prior treatment for NSCLC: Surgery(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| Yes | 9 | 9 | 18 |
| No | 35 | 47 | 82 |
| Prior treatment for NSCLC: Radiotherapy(Participants) | Squamous Non-small Cell Lung Cancer (NSCLC) | Non-squamous Non-small Cell Lung Cancer (NSCLC) | Total |
|---|---|---|---|
| Yes | 11 | 13 | 24 |
| No | 33 | 43 | 76 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2014 to primary completion in Nov 2015, 17 months.
Results were first posted in Dec 2024, 9 years 1 month after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 17 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →